Affiliation: Harvard University
- American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assaysHarold J Burstein
Dana Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 29:3328-30. 2011..To update the American Society of Clinical Oncology (ASCO) Technology Assessment guidelines on chemotherapy sensitivity and resistance assays (CSRAs) published in 2004...
- Evolving role of neoadjuvant therapy in rectal cancerDeborah Schrag
Dana Farber Cancer Institute, Boston, MA, 02215, USA
Curr Treat Options Oncol 14:350-64. 2013..To determine if therapy can be streamlined, participation in PROSPECT or other clinical trials asking compelling clinical questions is a priority...
- Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancerHanna K Sanoff
Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA
J Natl Cancer Inst 104:211-27. 2012..However, RCT participants are younger, healthier, and less racially diverse than the general cancer population. Thus, the benefit of oxaliplatin outside RCTs is uncertain...
- Linking tumor registry and Medicaid claims to evaluate cancer care deliveryDeborah Schrag
Dana Farber Cancer Institute, Boston, MA 02116, USA
Health Care Financ Rev 30:61-73. 2009..We found that Medicaid claims have moderate sensitivity for identifying cancer diagnoses and surgery. Linked registry-Medicaid data can identify indigent patients and the timing of Medicaid coverage...
- Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and CaliforniaJennifer W Mack
Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
J Clin Oncol 31:2569-79. 2013..Medicare patients with advanced cancer have low rates of hospice use. We sought to evaluate hospice use among patients in Medicaid, which insures younger and indigent patients, relative to those in Medicare...
- Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 yearsHanna K Sanoff
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 30:2624-34. 2012..Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) benefits this group is unknown...
- Regional variation in spending and survival for older adults with advanced cancerGabriel A Brooks
Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
J Natl Cancer Inst 105:634-42. 2013..Medicare spending varies substantially across the United States. We evaluated the association between mean regional spending and survival in advanced cancer...
- Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancerThomas A Abrams
Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA TAA, DS, JAM, CSF IntrinsiQ, LLC, an AmerisourceBergen Specialty Group Company, Burlington, MA GM, JM
J Natl Cancer Inst 106:djt371. 2014..Since the introduction of biologic therapies for the treatment of metastatic colorectal cancer (mCRC), few studies have examined patterns of care or predictors of specific treatment approaches...
- Expectations about the effectiveness of radiation therapy among patients with incurable lung cancerAileen B Chen
Dana Farber Cancer Institute, 450 Brookline Ave, D1111, Boston, MA 02215, USA
J Clin Oncol 31:2730-5. 2013..Although radiation therapy (RT) can palliate symptoms and may prolong life, it is not curative for patients with metastatic lung cancer. We investigated patient expectations about the goals of RT for incurable lung cancers...
- Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancerJunya Zhu
Center for Patient Safety, Dana Farber Cancer Institute, Boston, MA 02215, USA
Cancer 119:2048-60. 2013..Their relative effectiveness and comparability based on squamous versus nonsquamous histology is uncertain...
- Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancerRachel L Yung
Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
J Natl Cancer Inst 104:1102-5. 2012..Partnerships between Medicaid programs and cancer registries may help identify at-risk women and facilitate the implementation of quality improvement strategies...
- Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Oncologist 18:377-8. 2013..We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor)...
- Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysisHanna K Sanoff
Department of Medicine, Division of Hematology and Oncology, University of Virginia, Charlottesville, Virginia, USA
Cancer 118:4309-20. 2012..However, the tolerability of this in the general population of patients with colon cancer is uncertain...
- Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancerJunya Zhu
Center for Patient Safety, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
JAMA 307:1593-601. 2012..However, longer survival was not observed in the subgroup of patients aged 65 years or older...
- Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancerJeffrey A Meyerhardt
Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
J Clin Oncol 30:608-15. 2012..Clinical trials have shown that adding bevacizumab to cytotoxic chemotherapy improves survival for patients with colorectal cancer, although its effectiveness in the Medicare population is uncertain...
- Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 StudyJeffrey A Meyerhardt
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 22:166-74. 2004..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
- Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumorsGeoffrey Y Ku
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Invest 27:402-6. 2009..We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan...
- Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancerThomas A Abrams
Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 29:3255-62. 2011..Previous studies have examined predictors for initiation of adjuvant chemotherapy in stages II and III colon cancer. However, little is known regarding the use of specific chemotherapy regimens or treatment duration...
- Identification of potentially avoidable hospitalizations in patients with GI cancerGabriel A Brooks
All authors Dana Farber Cancer Institute, Boston, MA
J Clin Oncol 32:496-503. 2014..To identify and characterize potentially avoidable hospitalizations in patients with GI malignancies...
- Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303)Dorothy Romanus
Massachusetts General Hospital, Harvard School of Public Health, Boston, Massachusetts, USA
J Pain Symptom Manage 43:205-17. 2012..Gemcitabine for advanced pancreatic cancer (APC) is palliative and the prognosis is poor, making health-related quality of life (HRQOL) particularly important...
- Secular trends in colon and rectal cancer relative survivalCarolyn M Rutter
Affiliations of authors Group Health Research Institute, Seattle, WA CMR, EAJ Division of Cancer Control and Population Sciences National Cancer Institute, Bethesda, MD EJF Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Boston MA ABK Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis MN KMK Division of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA DS
J Natl Cancer Inst 105:1806-13. 2013..Relative survival is a metric that accounts for these concurrent changes, allowing assessment of changes in CRC survival. We describe stage- and location-specific trends in relative survival after CRC diagnosis...
- Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) StudyAileen B Chen
Dana Farber Cancer Institute, 450 Brookline Ave, D1111, Boston, MA 02215, USA
J Clin Oncol 31:558-64. 2013..We investigated population-based patterns in the use of palliative RT among patients with metastatic non-small-cell lung cancer (NSCLC)...
- Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
PLoS ONE 7:e38231. 2012..To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer...
- Patients' expectations about effects of chemotherapy for advanced cancerJane C Weeks
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
N Engl J Med 367:1616-25. 2012..Chemotherapy for metastatic lung or colorectal cancer can prolong life by weeks or months and may provide palliation, but it is not curative...
- Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort studyS Yousuf Zafar
Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
BMC Cancer 11:354. 2011..We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment...
- Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinomaBrian M Wolpin
Dana Farber Cancer Institute, Boston, Massachusetts, USA Brigham and Women s Hospital, Boston, Massachusetts, USA
Oncologist 19:637-8. 2014..We evaluated hydoxychloroquine (HCQ), an inhibitor of autophagy, in patients with pancreatic cancer and analyzed pharmacodynamic markers in treated patients and mice...
- Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patientsCraig C Earle
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Natl Cancer Inst 98:172-80. 2006..e., better outcomes). We examined associations between physician specialty and outcomes in a population-based cohort of elderly ovarian cancer surgery patients...
- Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrenceJeffrey A Meyerhardt
Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Ann Intern Med 139:649-57. 2003..However, because such administrative data lack information on cancer recurrence, the true nature of this relation remains uncertain...
- Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysisDavid J Sher
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 81:e197-206. 2011....
- What do cancer patients worry about when making decisions about treatment? Variation across racial/ethnic groupsMichelle Y Martin
Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, 1717 11th Avenue South, MT 617, Birmingham, AL, 35205, USA
Support Care Cancer 22:233-44. 2014..Understanding the source of patient worry and identifying interventions to alleviate worry are important to delivering patient-centered cancer care...
- Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptionsGregory A Abel
Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
Cancer 119:1065-72. 2013....
- Modeling the effectiveness of initial management strategies for ductal carcinoma in situDjøra I Soeteman
Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
J Natl Cancer Inst 105:774-81. 2013..We sought to quantify the tradeoffs among alternative management strategies for DCIS with respect to disease outcomes and breast preservation...
- Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studiesTeppei Morikawa
Department of Medical Oncology, Dana Farber Cancer Institute and Havard Medical School, Boston, MA 02215, USA
Arch Surg 147:715-23. 2012..To identify factors that influence the total and negative lymph node counts in colorectal cancer resection specimens independent of pathologists and surgeons...
- Receipt of appropriate surgical care for Medicare beneficiaries with cancerCaprice C Greenberg
Center for Surgery and Public Health, Department of Surgery, Brigham and Women s Hospital, Boston, MA 02115, USA
Arch Surg 146:1128-34. 2011..To investigate receipt of appropriate surgical care in Medicare beneficiaries with cancer...
- Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among medicare patients with stage III lung cancerAileen B Chen
Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA and Dana Farber Cancer Institute, Boston, MA
J Thorac Oncol 9:1788-95. 2014..The clinical benefit of intensity-modulated radiation therapy (IMRT) compared to 3D conformal radiation (3D-RT) has not been well established for locally advanced non-small-cell lung cancer (NSCLC)...
- Stakeholder engagement for comparative effectiveness research in cancer care: experience of the DEcIDE Cancer ConsortiumCaprice C Greenberg
Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA, USA
J Comp Eff Res 2:117-25. 2013..These recommendations can inform other initiatives currently facing the challenges of engaging stakeholders in priority setting for cancer. ..
- Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutionsMarsha Reyngold
From aDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York bDepartments of Information Sciences and cBiostatistics, City of Hope Comprehensive Cancer Center, Duarte, California dDepartment of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts eDivision of Medical Oncology, Department of Medicine, The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, Columbus, Ohio fDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania gDepartment of Surgical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California hDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas iDepartment of Radiation Oncology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois jDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York and kDepartment of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York
J Natl Compr Canc Netw 12:235-43. 2014....
- Delivering high-quality and affordable care throughout the cancer care continuumYa Chen Tina Shih
Ya Chen Tina Shih, University of Chicago, Chicago IL Patricia A Ganz, Denise Aberle, and Jim C Hu, University of California at Los Angeles, Los Angeles, CA Amy Abernethy, Duke University, Durham, NC Justin Bekelman, University of Pennsylvania, Philadelphia, PA Otis Brawley, American Cancer Society, Atlanta, GA James S Goodwin, University of Texas, Galveston, TX Deborah Schrag, Dana Farber Cancer Institute and Jennifer S Temel and Lowell Schnipper, Harvard Medical School, Boston, MA
J Clin Oncol 31:4151-7. 2013..This article is our summary of presentations at the workshop that highlighted the overuse and underuse of screening, treatments, and technologies throughout the cancer care continuum in oncology practice in the United States. ..
- Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancyNadine J McCleary
Dana Farber Cancer Institute, Department of Medical Oncology, Gastrointestinal Oncology, 450 Brookline Avenue, Boston, MA 02215, USA
Oncologist 18:64-72. 2013..The Cancer-Specific Geriatric Assessment (CSGA) is a primarily self-administered paper survey of validated measures...
- Rescreening of persons with a negative colonoscopy result: results from a microsimulation modelAmy B Knudsen
Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, 10th Floor, Boston, MA 02114, USA
Ann Intern Med 157:611-20. 2012..Persons with a negative result on screening colonoscopy are recommended to repeat the procedure in 10 years...
- Phase 1/2 study of everolimus in advanced hepatocellular carcinomaAndrew X Zhu
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
Cancer 117:5094-102. 2011..The phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma (HCC). We performed a single-arm, phase 1/2 study of everolimus in patients with advanced HCC...
- Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulationAileen B Chen
Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
J Clin Oncol 29:2305-11. 2011..Technical studies suggest that computed tomography (CT) -based simulation improves the therapeutic ratio for thoracic radiation therapy (TRT), although few studies have evaluated its use or impact on outcomes...
- Cancer disparities in the context of Medicaid insurance: a comparison of survival for acute myeloid leukemia and Hodgkin's lymphoma by Medicaid enrollmentRachel L Yung
Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Oncologist 16:1082-91. 2011..Using Medicaid enrollment as a proxy for poverty, we aimed to assess potential disparities in survival after a diagnosis of acute myeloid leukemia (AML) or Hodgkin's lymphoma (HL) in a nonelderly population...
- American Society of Clinical Oncology guidance statement: the cost of cancer careNeal J Meropol
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
J Clin Oncol 27:3868-74. 2009..Doing so will require a clear understanding of the factors that drive these costs, as well as potential modifications to the current cancer care system to ensure that all Americans have access to high-quality, cost-effective care...
- Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS)Hajime Uno
Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Leuk Res 38:1420-4. 2014..Risk stratification by the SMMRS was comparable to the IPSS (net reclassification improvement index was 0.0), demonstrating that it is a useful research tool to stratify MDS patients in studies using SEER-Medicare. ..
- Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancerWilliam P Tew
Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Invest New Drugs 27:366-73. 2009..To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies...
- Using propensity scores to estimate the cost-effectiveness of medical therapiesAlka Indurkhya
Department of Society, Human Development and Health, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
Stat Med 25:1561-76. 2006..Our method is illustrated by applying it to SEER-Medicare data for muscle invasive bladder cancer to determine the most cost-effective treatment protocol...
- Patient-oncologist cost communication, financial distress, and medication adherenceChristine M Bestvina
Duke Cancer Institute Duke Clinical Research Institute Durham Veterans Affairs Medical Center, Durham University of North Carolina, Chapel Hill, NC and Dana Farber Cancer Institute, Boston, MA
J Oncol Pract 10:162-7. 2014..Little is known about the association between patient-oncologist discussion of cancer treatment out-of-pocket (OOP) cost and medication adherence, a critical component of quality cancer care...
- Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resectionDeborah Schrag
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Department of Medicine, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Ann Surg 236:583-92. 2002..To compare surgeon and hospital procedure volume as predictors of outcomes for patients with rectal cancer...
- Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysisDorothy Romanus
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Natl Compr Canc Netw 7:895-904. 2009..The Colorectal Cancer Database began in 2005 as a collaboration among 8 NCCN centers...
- Cetuximab therapy and symptomatic hypomagnesemiaDeborah Schrag
Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 221, New York, NY 10011, USA
J Natl Cancer Inst 97:1221-4. 2005..Because symptoms may be rapidly ameliorated with supplementation, we suggest that, when fatigue or hypocalcemia is encountered during cetuximab therapy, serum magnesium level be measured and repleted as necessary...
- Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicitiesEthan Basch
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Am Med Inform Assoc 14:264-8. 2007..Ongoing multi-center research will evaluate the impact of this approach on clinical and administrative outcomes...
- A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemicElizabeth Y Chiao
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Acquir Immune Defic Syndr 40:451-5. 2005..The incidence of SCCA has particularly increased among men and those between 30 and 54 years of age since the introduction of HAART...
- Religious coping and use of intensive life-prolonging care near death in patients with advanced cancerAndrea C Phelps
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
JAMA 301:1140-7. 2009..Patients frequently rely on religious faith to cope with cancer, but little is known about the associations between religious coping and the use of intensive life-prolonging care at the end of life...